AZ

Explore the latest insights on AZ and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of AZ’s developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.
Explore the latest insights on AZ and its impact on China's pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of AZ's developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

GSK Reports First Global Data for B7‑H3 ADC Risvutatug Rezetecan – 61% Confirmed ORR at 8 mg/kg in Relapsed ES‑SCLC Phase Ib
CompanyDrug

GSK Reports First Global Data for B7‑H3 ADC Risvutatug Rezetecan – 61% Confirmed ORR at 8 mg/kg in Relapsed ES‑SCLC Phase Ib

GlaxoSmithKline Plc (GSK; NYSE: GSK) announced the first global data for risvutatug rezetecan (Ris‑Rez, HS‑20093), its investigational B7‑H3‑targeted antibody‑drug conjugate (ADC), in patients with relapsed extensive‑stage small cell lung cancer…

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance

Qingfeng Pharmaceutical Signs Five‑Year Strategic Collaboration with China Association Against Epilepsy – Advancing Discipline Development, Talent Cultivation and Patient Assistance

Biohaven Licenses MoDE Pan‑IgG Degrader Portfolio to Ono Pharmaceutical in Asia – Up to USD 100 Million in Near‑Term Payments for BHV‑1300 Franchise

Biohaven Licenses MoDE Pan‑IgG Degrader Portfolio to Ono Pharmaceutical in Asia – Up to USD 100 Million in Near‑Term Payments for BHV‑1300 Franchise

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Company

AstraZeneca Restructures to Capture Opportunities in Guangdong-Hong Kong-Macao Greater Bay Area

CompanyLegal / IP

Scott-Moncrieff & Associates Preparing 50 Cases Against AstraZeneca Over Vaccine Concerns

CompanyDrug

AstraZeneca’s Forxiga Demonstrates Clinical Benefits in Heart Failure and COPD Patients

Drug

AstraZeneca’s Forxiga Gains New Indication Approval in China for Chronic Heart Failure

CompanyDeals

Amoy Diagnostics and AstraZeneca Expand Collaboration on Companion Diagnostic Development

CompanyDeals

AstraZeneca to Invest Additional USD 250 Million in Qingdao for Aerosol Production Plant

CompanyDeals

Burning Rock Partners with AstraZeneca to Develop Companion Diagnostics for Cancer Therapies

CompanyDeals

CanSino Biotechnology Partners with AstraZeneca for mRNA Vaccine Development and Manufacturing

Show More